Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
LLY US​

Eli Lilly and Company(LLY US)

$1,273.46-33.232.54%Ext:$1,268.43-5.030.39%(Market Closed · 00:00:00 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Eli Lilly and Company — Company Profile

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
David A. Ricks
Headquarters
Indianapolis, IN, US
IPO Date
Jun 1, 1972
Employees
50,000
Website
www.lilly.com

Key Metrics

Price
$1142.85
Market Cap
$1.08T
Revenue (TTM)
$19.80B
Net Income (TTM)
$7.40B
EPS (TTM)
8.27
P/E (TTM)
42.58
P/B (TTM)
34.50
Dividend Yield
64.28%
ROE (TTM)
23.71%
ROA (TTM)
6.34%
Operating Margin
44.70%
Beta
0.30

Dividends

Last Dividend
$1.73
Last Yield
0.64%

Summary

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Website
www.lilly.com
Location
Indianapolis, IN, US
Phone317 276 2000
Employees50,000
CEODavid A. Ricks
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJun 1, 1972

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(3.9K)

Expand
  • 3Initial statement of beneficial ownership22 Oct
  • 4Statement of changes in beneficial ownership20 Oct
  • 4Statement of changes in beneficial ownership20 Oct
  • 4Statement of changes in beneficial ownership20 Oct
  • 4Statement of changes in beneficial ownership20 Oct
  • SC 13G/AELI LILLY & Co19 Oct
  • SC 13DTRex Bio, Inc.16 Oct
  • 144LILLY ENDOWMENT INC15 Oct
  • 3Initial statement of beneficial ownership8 Oct
  • 144LILLY ENDOWMENT INC7 Oct
  • 4Statement of changes in beneficial ownership22 Sep
  • 4Statement of changes in beneficial ownership22 Sep
  • 4Statement of changes in beneficial ownership22 Sep
  • 4Statement of changes in beneficial ownership22 Sep
  • 4Statement of changes in beneficial ownership11 Sep
  • 3/AInitial statement of beneficial ownership (amendment)4 Sep
  • 4Statement of changes in beneficial ownership4 Sep
  • 4Statement of changes in beneficial ownership4 Sep
  • 4Statement of changes in beneficial ownership18 Aug
  • 4Statement of changes in beneficial ownership18 Aug

EDINET Filings(1)

Expand
  • MRQLarge-scale holdings report4 Jul 2024

News

  • Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 202602:30AM
  • Eli Lilly CEO previews the next generation of weight-loss drugs12:00AM
  • 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)23 Oct
  • Eli Lilly Stocks Slip 1.7% Ahead of Earnings After 48% Revenue Growth23 Oct
  • Eli Lilly (LLY) Price Forecast: Breakout Strengthens Ahead of Earnings22 Oct
  • UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom22 Oct
  • Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 202022 Oct
  • Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?22 Oct
  • 449 Shares in Eli Lilly and Company $LLY Purchased by Boyd Wealth Management LLC22 Oct
  • Eli Lilly and Company $LLY Stock: Bank Pictet & Cie Europe AG Reduces Holdings22 Oct
  • Eli Lilly and Company $LLY Stock Purchased by Diversify Advisory Services LLC22 Oct
  • Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss21 Oct
  • Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know21 Oct
  • Here's What I'm Planning With My Eli Lilly Position20 Oct
  • Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher20 Oct
  • Stock Market Midday, Oct. 20: Blue Chips Rally, Eli Lilly Gains 5%20 Oct
  • Dow Up 523 Points as Market Momentum Grows20 Oct
  • If Eli Lilly Grows At 10% a Year, Here's What $1,000 Becomes By 203020 Oct
  • Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts19 Oct
  • Tech Stocks Rebound From Heavy Losses Before Big Earnings Reports; Apple, Lilly Eye Buy Points19 Oct

Mentions in Filings

  • … nnel as we scale up our operations. Once we are a public company, we will incur additional costs associated with operating as a public company. To date, we have funded our operations primarily through the sale of convertible preferred stock, convertible notes and collaboration revenue from our collaboration agreement with <strong>Eli Lilly and Company</strong> (Lilly). As of June 30, 2026, we had cash, cash equivalents and marketable securities of $148.1 million.
    Lycia Therapeutics, Inc.Eli Lilly and Company·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·23 Oct
  • … logy companies, such as Amgen Inc., Apogee Therapeutics, Inc. (acquired by AbbVie Inc.), AstraZeneca plc, Belenos Biosciences Inc., Generate Biomedicines, Inc., GSK plc, Johnson & Johnson, KeyMed Biosciences Inc., <strong>Eli Lilly and Company</strong>, Pfizer Inc., Sanofi S.A., and Upstream Bio, Inc. that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competi …
    WINDWARD BIO GROUP AGEli Lilly and Company·F-1 - Registration statement (foreign issuer)·Q4 26·23 Oct
  • … technology company, since May 2023. She previously served as Executive Chair of the board of directors of Ventyx Biosciences, Inc., a publicly held biopharmaceutical company, from May 2021 until its acquisition by <strong>Eli Lilly and Company</strong> in January 2026, chair of the board of directors of ADARx Pharmaceuticals, Inc., a privately held biopharmaceutical company, from June 2020 to January 2025, chair of the board of directors of ImmPACT Bio USA Inc., …
    Bolt Biotherapeutics, Inc.Eli Lilly and Company·8-K - Entry into a Material Definitive Agreement·Q4 26·23 Oct
  • … member of the Treeline Board since April 2021. Previously, he was chief executive officer of Loxo Oncology, Inc., or Loxo Oncology, a cancer-focused biotechnology company, from July 2013 through its acquisition by <strong>Eli Lilly and Company</strong> in 2019, after which he continued leading Loxo Oncology at Lilly until January 2021. Dr. Bilenker co-founded and was the chief executive officer of Loxo Oncology from 2013 to 2019. From 2006 to 2013, Dr. Bilenker w …
    STANDARD BIOTOOLS INC.Eli Lilly and Company·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·21 Oct
  • … tion of certain intellectual property and other assets under an asset contribution arrangement and (ii) an aggregate of 648,030 shares issued in exchange for the termination of a purchase option previously held by <strong>Eli Lilly and Company</strong> in March and June of 2019. ​ ▪ Series B Preferred Stock: Beginning in May 2020, we raised aggregate net proceeds of approximately $59.3 million through the issuance of Series B1 convertible preferred stock, or t …
    Rezera Inc.Eli Lilly and Company·S-1 - Registration statement (general form)·Q4 26·21 Oct
  • … undertaking (other than an Investor (as such term is defined in that certain Investors’ Agreement by and among the Corporation and the stockholders party thereto dated September 20, 2022), Ryvu Therapeutics, S.A., <strong>Eli Lilly and Company</strong>, or an undertaking which the Corporation and the Requisite Holders have agreed in writing to be exempt from the provisions of this Section 2(i)(4)) of this Appendix A, and it (or its parent undertaking) is subject …
    Rezera Inc.Eli Lilly and Company·EX-3.3 - S-1 - Registration statement (general form)·Q4 26·21 Oct

Key Stats

Trading

Px/Chg 1D$1,142.85 / -0.61%
Avg Volume3.16M
Beta0.30
Mkt Cap1.08T
FD Mkt Cap1.09T

Float

Shrs Out/Float941.74M / 848.69M
Short Float0.01%
Days to Cover2.58
Stock Repurchased$2.36B

Current Valuation

EV1.11T
EV/EBITDA33.30
EV/Sales15.43
P/B34.50
P/S14.90
FCF Yield0.28%
ROE23.71%
ROA6.34%
Current Ratio1.50

Dividend

Cash$1.73
Yield64.28%
Yield (TTM)64.28%

Estimates

P/E42.58
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings104.1957.25126.5276.45115.19145.52
Price / Sales28.7812.5319.4317.9739.6254.36
Price / Book Value43.0933.5761.5557.0528.8134.50
Price / Free Cash Flow661.4077.72-210.351,954.141,127.58357.92
ENTERPRISE VALUE METRICS
Enterprise Value762,325.6371,822.2685,520.7840,054.2799,728.31,114,502.7
Enterprise Value / Sales29.9013.0320.0918.6541.4556.29
Enterprise Value / EBITDA77.6942.9380.0155.1795.34115.00
Enterprise Value / EBIT86.0752.0997.3762.4197.10121.38

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue23.2%28,318.428,541.434,124.145,042.765,179.0
Gross Income27%21,005.621,911.627,041.936,624.454,615.0
EBITDA36.5%8,042.98,660.58,567.815,227.627,936.5
EBIT42%6,495.37,138.07,040.513,461.026,373.0
Net Income38.7%5,581.76,244.85,240.410,590.020,638.3
EPS (Diluted)40.7%5.856.575.8011.7122.95
BALANCE SHEET
Cash & ST Inv16.8%3,908.62,211.82,927.73,423.27,268.0
Total Assets23.2%48,806.049,489.864,006.378,714.9112,476.0
Total Liabilities21.3%39,651.238,714.453,142.664,443.385,941.0
Total Shareholder Equity31.1%8,979.210,649.810,771.914,192.126,535.0
CASH FLOW
Net Operating Cash Flow22.9%7,365.97,585.74,240.18,817.916,813.0
Cap Ex41.1%-1,978.4-2,985.3-7,392.1-8,403.6-7,841.0
Free Cash Flow13.6%5,387.54,600.4-3,152.0414.38,972.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)1,270.00
Basic Shares941.74
Market Cap1,196,011.1
Diluted Shares895.90
Fully Diluted Shares Outstanding895.90
Fully Diluted Market Cap1,137,793.0
+Consolidated Debt43,370.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-5,136.0
−Short-term Investments-146.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value1,234,245.1

Segment data

Revenue

by Products and services

  • Product94%
  • Collaboration And Other Revenue6%

Revenue

by Geography

  • United States67%
  • Europe18%
  • Non-us9%
  • Japan3%
  • China3%

Related companies

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US